BACKGROUND AND AIM: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. METHODS: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcer patients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. RESULTS: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcer patients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcer patients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. CONCLUSION: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.
BACKGROUND AND AIM: Emerging data indicate that serum trefoil factors (TFFs), especially TFF3, could be potential biomarkers for gastric cancer risk. We aimed to evaluate the influence of Helicobacter pylori (H. pylori) status and eradication on serum TFFs and the pepsinogen test. METHODS: Healthy individuals who underwent a thorough medical checkup were enrolled in study 1, and gastric ulcerpatients who undertook H. pylori eradication therapy were enrolled in studies 2 and 3. Serum levels of the TFFs (TFF1, TFF2 and TFF3), H. pylori antibody and pepsinogen test were examined in all studies. In study 3, TFF expressions in biopsy samples of the gastric mucosa were additionally examined before and 2 months after eradication. RESULTS: In 1,260 healthy individuals enrolled in study 1, serum TFF1 and TFF2 levels were markedly different between H. pylori antibody-positive and -negative participants (P < 0.0001). Differences in serum TFF3 levels between H. pylori antibody-positive (5.85 ± 3.93 ng/ml) and -negative subjects (5.27 ± 2.38 ng/ml) were statistically significant (P = 0.002) but small in absolute value. In 178 gastric ulcerpatients enrolled in study 2, serum TFF1, TFF2 and positive rates of the pepsinogen test significantly decreased 2 months after H. pylori eradication therapy (P < 0.001). In contrast, serum TFF3 levels and positive rates of high TFF3 levels (≥7 ng/ml) did not significantly change with H. pylori-eradication until 5 years after eradication. In 18 gastric ulcerpatients (study 3), TFF1 and TFF2 were mainly expressed in the foveolar epithelium, and TFF2 was additionally expressed in the pyloric glands. These expressions significantly decreased with H. pylori eradication. TFF3s were scarcely expressed in the gastric mucosa except in goblet cells of intestinal metaplasia, which did not change with H. pylori eradication. CONCLUSION: In serum TFFs and pepsinogen tests, only serum TFF3s were not significantly affected by H. pylori eradication, suggesting that serum TFF3 could be a stable biomarker of gastric cancer risk even after H.pylori eradication in contrast with the pepsinogen test.
Authors: K Miki; M Ichinose; N Kakei; N Yahagi; M Matsushima; S Tsukada; S Ishihama; Y Shimizu; T Suzuki; K Kurokawa Journal: Adv Exp Med Biol Date: 1995 Impact factor: 2.622
Authors: T Kawai; K Miki; M Ichinose; Y Kenji; I Miyazaki; K Kawakami; M Kataoka; T Yamagishi; A Sofuni; T Itoi; F Moriyasu; Y Takagi; T Aoki; J Matsubayashi; K Mukai Journal: Inflammopharmacology Date: 2007-02 Impact factor: 4.473
Authors: Anthony J Peterson; Trevelyan R Menheniott; Louise O'Connor; Anna K Walduck; James G Fox; Kazuyuki Kawakami; Toshinari Minamoto; Eng Kok Ong; Timothy C Wang; Louise M Judd; Andrew S Giraud Journal: Gastroenterology Date: 2010-08-27 Impact factor: 22.682
Authors: Jo K Perry; Nagarajan Kannan; Prudence M Grandison; Murray D Mitchell; Peter E Lobie Journal: Trends Endocrinol Metab Date: 2007-12-03 Impact factor: 12.015
Authors: E Bignotti; A Ravaggi; R A Tassi; S Calza; E Rossi; M Falchetti; C Romani; E Bandiera; F E Odicino; S Pecorelli; A D Santin Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640
Authors: A Shiotani; T Murao; Y Kimura; H Matsumoto; T Kamada; H Kusunoki; K Inoue; N Uedo; H Iishi; K Haruma Journal: Br J Cancer Date: 2013-10-08 Impact factor: 7.640